Burton-on-Trent, UK – 16 February 2015 – Clinigen Group plc (AIM: CLIN), the global specialty pharmaceuticals and services company, will announce its half year results for the six months ended 31 December 2014 on Tuesday, 3 March 2015.
A group analyst briefing will be held at 9:30am on Tuesday, 3 March 2015 at Instinctif Partners’ offices at 65 Gresham Street, London EC2V 7NQ. Analysts who wish to participate should contact Instinctif Partners on +44 (0)20 7457 2020 or email firstname.lastname@example.org to register.
- Ends -
About Clinigen Group
The Clinigen Group is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group, dedicated to delivering ‘the right drug, to the right patient at the right time’, has three operating businesses; Specialty Pharmaceuticals (SP), Clinical Trials Supply (CTS), and Global Access Programs (GAP). SP focuses on acquiring and in licensing specialist, hospital only medicines worldwide and commercializing them within niche markets. CTS sources commercial medical products for use in clinical studies only, including comparator drugs, adjuvant drugs and rescue therapies. GAP specializes in the consultancy, development, management and implementation of programs providing access for patients and their clinicians to drugs not available in their markets.
For more information, please visit www.clinigengroup.com.
Clinigen Group plc
Tel: +44 (0) 1283 495 010
Peter George, Group Chief Executive Officer
Robin Sibson, Group Chief Financial Officer
Shaun Chilton, Group Chief Operating Officer
Numis Securities Limited
Tel: +44 (0) 20 7260 1000
Michael Meade/Freddie Barnfield (Nominated Adviser)
James Black/Tom Ballard (Corporate Broking)
Peel Hunt LLP – Joint Broker
Tel: +44 (0) 20 7418 8900
James Steel / Jock Maxwell Macdonald
Instinctif Partners - Media Relations
Tel: +44 (0) 20 7457 2020
Melanie Toyne-Sewell/Jen Lewis/Emma Barlow